Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Asset Writedowns and Impairment (2023 - 2024)

Lyra Therapeutics (LYRA) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $17000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Asset Writedowns and Impairment rose 112.5% to $17000.0 in Q4 2024 year-over-year; TTM through Jun 2025 was $1.9 million, a 45.45% decrease, with the full-year FY2024 number at $1.9 million, up 18.75% from a year prior.
  • Asset Writedowns and Impairment was $17000.0 for Q4 2024 at Lyra Therapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.9 million in Q2 2024 to a low of $8000.0 in Q4 2023.